SynthesisEndocrine-related cancer2018
Genetic testing for indeterminate thyroid cytology: review and meta-analysis.
Synthesis in Endocrine-related cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Comparing the diagnostic accuracy of Afirma GSC to ThyroSeq V3 in cytologically indeterminate thyroid nodules.European thyroid journal · 2025Pooled it
- Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.Thyroid : official journal of the American Thyroid Association · 2022Pooled it
- Health-Related Quality of Life following Total Thyroidectomy and Lobectomy for Differentiated Thyroid Carcinoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2022Pooled it
- Impact of Molecular Testing on the Management of Indeterminate Thyroid Nodules Among Western and Asian Countries: a Systematic Review and Meta-analysis.Endocrine pathology · 2021Pooled it
- Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule.Diagnostic cytopathology · 2019Pooled it
- ThyroidPrint: Thyroid Genetic Classifier Long-Term Follow-Up of Benign Called Lesions.Clinical endocrinology · 2026Article
- The role of insurance status in molecular testing for thyroid nodules with indeterminate cytology.Journal of the Endocrine Society · 2026Article
- Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing.Clinical endocrinology · 2026Article
- The role of artificial intelligence in thyroid cytology of indeterminate nodules: from digital cytology to multimodal precision triage.Frontiers in endocrinology · 2026Review
- External validation of a microRNA thyroid classifier: a real-world prospective study.European thyroid journal · 2025Observational
- Comparing the diagnostic accuracy of pre-operative genetic testing for thyroid cancer on fine needle aspiration cytology specimens: a systematic review and meta-analysis of diagnostic accuracy.Discover oncology · 2025Article
- Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review.Diagnostics (Basel, Switzerland) · 2025Review
- Serum microRNA analysis facilitates decision-making between active surveillance and immediate surgery for low-risk thyroid tumors.Archives of endocrinology and metabolism · 2025Article
- Deep learning-based cell segmentation for rapid optical cytopathology of thyroid cancer.Scientific reports · 2024Article
- Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis.Endocrine connections · 2024Article
- Molecular testing for thyroid nodules: Where are we now?Reviews in endocrine & metabolic disorders · 2024Review
- The diagnostic and prognostic role of miR-146b-5p in differentiated thyroid carcinomas.Frontiers in endocrinology · 2024Article
- Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.ESMO open · 2023Article
- ThyroidPrint®: clinical utility for indeterminate thyroid cytology.Endocrine-related cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer is the most frequent endocrine malignancy, and its incidence is increasing. A current limitation of cytological evaluation of thyroid nodules is that 20-25% are reported as indeterminate. Therefore, an important challenge for clinicians is to determine whether an indeterminate nodule is malignant, and should undergo surgery, or benign, and should be recommended to follow-up. The emergence of precision medicine has offered a valuable solution for this problem, with four tests currently available for the molecular diagnosis of indeterminate cytologies. However, efforts to critically analyze the quality of the accumulated evidence are scarce. This systematic review and meta-analysis is aimed to contribute to a better knowledge about the four available molecular tests, their technical characteristics, clinical performance, and ultimately to help clinicians to make better decisions to provide the best care options possible. For this purpose, we address three critical topics: (i) the proper theoretical accuracy, considering the intended clinical use of the test (rule-in vs rule-out) and the impact on clinical decisions; (ii) the quality of the evidence reported for each test (iii) and how accurate and effective have the tests proved to be after their clinical use. Together with the upcoming evidence, this work provides significant and useful information for healthcare system decision-makers to consider the use of molecular testing as a public health need, avoiding unnecessary surgical risks and costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.